Overview

Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.
Phase:
Phase 1
Details
Lead Sponsor:
Deltanoid Pharmaceuticals
Treatments:
Calcitriol